🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Dresden
Clinical trial register · Germany

Clinical Trials in Dresden, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Technische Universität Dresden42 Janssen Research & Development, LLC33 Novartis Pharmaceuticals29 Merck Sharp & Dohme LLC22
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Dresden

707 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Bad Oeynhausen, Berlin, Brandenburg, Dresden, Düsseldorf, Frankfurt, Hanover, Heidelberg
2025-10-15
By invitation
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
NCT07032246Multiple Sclerosis, Radiologically Isolated Syndrome, Clinically Isolated Syndrome
icometrix
Not applicable
750
Bochum, Dresden, Berlin
2025-10-09
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488Multiple Myeloma
DrugsMezigdomide·Elranatamab·Dexamethasone
Celgene
Phase 1/2
62
Dresden, Hamburg, Heidelberg
2025-10-07
Recruiting
Study to Evaluate the Performance of Navigated TKA With OrthoPilot® pheno4u TKA Level 1
NCT06955481Osteoarthritis, Knee, Joint Diseases, Rheumatoid Arthritis of Knee, Posttraumatic Arthropathy
Aesculap AG
Observational
120
Konstanz, Berlin, Dresden
2025-10-07
Not yet open
AI-based Progression and Medication Response Prediction Study in Parkinson's Disease
NCT07189468PARKINSON DISEASE (Disorder)
University Hospital, Toulouse
Observational
100
Dresden
2025-10-06
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
DrugPonsegromab
Pfizer
Phase 2/3
982
München, Düsseldorf, Dresden, Leipzig, Berlin
2025-10-03
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel
2025-10-02
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Tübingen, Ulm, Würzburg, Remscheid, Ludwigshafen am Rhein, Dresden, Leipzig, Jerichow
2025-10-01
Recruiting
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
NCT07008118Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
120
Dresden, Halle, Mainz
2025-10-01
Recruiting
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
NCT07197866Multiple System Atrophy
DrugEmrusolmin
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
Dresden, Düsseldorf, Kassel, Marburg, München, Münster
2025-09-30
Recruiting
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
NCT06855134Rare Cancer
German Cancer Research Center
Observational
946
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2025-09-29
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
DrugsBNT326·Pumitamig
BioNTech SE
Phase 1/2
880
Dresden, Freiburg im Breisgau, Heidelberg
2025-09-22
Recruiting
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
NCT06765226Heart Failure
Abiomed Inc.
Observational
200
Heidelberg, Düsseldorf, Dresden, Leipzig, Berlin, Cologne, Essen
2025-09-21
Recruiting
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Phase 2
240
Dresden, Hanover, Jena, Lübeck, Rostock, Ulm
2025-09-17
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Bochum, Dresden, Hamburg, Hanover, Karlsruhe, Leipzig, München, Offenbach
2025-09-15
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
DrugDelgocitinib
LEO Pharma
Phase 2
135
Bad Bentheim, Dresden, Göttingen, Kiel, Lübeck, Manheim, Münster, Osnabrück
2025-09-11
Recruiting
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT07054190Breast Cancer
DrugsGiredestrant·Inavolisib·Ribociclib·Letrozole
Hoffmann-La Roche
Phase 2
120
Berlin, Dresden, Essen, Heidelberg, Paderborn, Schwerin
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hanover, Heidelberg
2025-09-08
Recruiting
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745Refractory Autoimmune Diseases
DrugsTocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Düsseldorf, Kiel, Berlin, Dresden, Hamburg
2025-09-04
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Aachen, Bad Homburg, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Greifswald
2025-09-02
Not yet open
Immune-Marker Platform for Patients With Advanced Lung Cancer
NCT07150598NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, NSCLC Non-small Cell Lung Cancer
Technische Universität Dresden
Observational
500
Cologne, Dresden
2025-09-01
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
DrugsCapivasertib·Fulvestrant
Relay Therapeutics, Inc.
Phase 3
540
Aschaffenburg, Bottrop, Dresden, Eggenfelden, Erlangen, Freiburg im Breisgau, Krefeld, Mannheim
2025-08-26
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin
Amgen
Phase 3
350
Chemnitz, Cologne, Dresden, Essen, Frankfurt am Main, Gauting, Großhansdorf, Kiel
2025-08-18
Recruiting
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
NCT07112339Diabetes Mellitus, Type 2
DrugInsulin icodec
Novo Nordisk A/S
Phase 4
586
Amberg, Bad Mergentheim, Bad Reichenhall, Berlin, Bünde, Daaden, Dortmund, Dresden
2025-08-15
Recruiting
SCORE Study: Comparing Surgery and Rigid Collar Treatment for Odontoid Fractures in Adults Over 70
NCT06961578Odontoid Fracture, Elderly
Technical University of Munich
Not applicable
322
Munich, Frankfurt am Main, Berlin, Aachen, Cologne, Dresden, Essen, Göttingen
2025-08-13
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
DrugsInsulin aspart·Insulin glargine·Insulin icodec
Novo Nordisk A/S
Phase 3
877
Bad Mergentheim, Bad Oeynhausen, Berlin, Bochum, Dresden, Eisenach, Essen, Gelnhausen
2025-08-11
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
400
Dresden, Münster
2025-08-08
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Düsseldorf, Essen
2025-08-06
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
DrugsTzield·Teplizumab
Sanofi
Phase 3
723
Augsburg, Bielefeld, Dresden, Frankfurt, Freiburg im Breisgau, Hanover, Leipzig, Munich
2025-08-06
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel
AstraZeneca
Phase 3
800
Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-08-01
Not yet open
Radiation-induced Toxicity of the Heart
NCT06986291Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
Technische Universität Dresden
Not applicable
325
Dresden
2025-08
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Sacituzumab tirumotecan·Leucovorin·Adrucil
Merck Sharp & Dohme LLC
Phase 1/2
298
Erdgeschoss, Düsseldorf, Dresden
2025-07-30
Active, closed
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
NCT06878365Type 1 Interferonopathies
Boehringer Ingelheim
Phase 1
16
Dresden, Hanover, Tübingen
2025-07-29
Recruiting
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
NCT07010159Pericarditis, Pericarditis Acute, Recurrent Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2/3
325
Dresden
2025-07-25
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
DrugAbrocitinib
Pfizer
Phase 3
150
Münster, Dresden
2025-07-24
Recruiting
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
NCT07145450PDAC
Anocca AB
Phase 1/2
96
Berlin, Dresden, Heidelberg, Leipzig, München, Tübingen
2025-07-03
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
DrugNucresiran
Alnylam Pharmaceuticals
Phase 3
1,750
Berlin, Cologne, Dresden, Göttingen, Hanover, Heidelberg, Leipzig, Magdeburg
2025-07-02
Not yet open
Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
NCT05647096Sepsis, Respiratory Failure
Santersus AG
Not applicable
73
Bonn, Dresden, Hannover
2025-07-01
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
DrugsCDK4/6i·Trastuzumab deruxtecan
MedSIR
Phase 2
200
Aschaffenburg, Augsburg, Dresden, Essen, Worms
2025-06-30
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-30
Active, closed
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT06966453Breast Cancer, Breast Neoplasms
DrugDisitamab Vedotin
Pfizer
Phase 1/2
74
Essen, Dresden, Berlin, Leipzig
2025-06-30
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-27
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Bad Berka, Bad Neustadt an der Saale, Bad Segeberg, Berlin, Bonn, Detmold, Dresden, Düsseldorf
2025-06-25
Recruiting
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
NCT05903833Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer
DrugsLenvatinib·Pembrolizumab
AGO Research GmbH
Phase 2
42
Augsburg, Bad Homburg, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Hanau
2025-06-24
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
580
Berlin, Bochum, Darmstadt, Dresden, Erlangen, Hamburg, Lübeck
2025-06-23
Recruiting
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
NCT06717958AML, MDS
DrugIvosidenib
Technische Universität Dresden
Phase 2
76
Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt am Main, Greifswald, Halle
2025-06-17
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
DrugRuxolitinib
Incyte Corporation
Phase 3
159
Bad Bentheim, Bonn, Chemnitz, Dresden, Frankfurt, Göttingen, Kiel, Mainz
2025-06-17
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
630
Berlin, Cologne, Dresden, Jena, Kiel, Mutlangen, München, Neubrandenburg
2025-06-11
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Berlin, Dresden, Leipzig
2025-06-10
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867Myelodysplastic Syndromes
DrugMomelotinib
GlaxoSmithKline
Phase 2
80
Münster, Dresden, Leipzig
2025-06-05
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490Multiple Sclerosis Spasticity
DrugIrafamdastat
Celgene
Phase 2
200
Würzburg, Kassel, Bochum, Münster, Meisenheim, Jena, Bielefeld, Dresden
2025-06-05
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839Macular Edema
Boehringer Ingelheim
Phase 2
300
Dresden, Düsseldorf, Leipzig, Mannheim, Münster
2025-06-05
Active, closed
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542Chronic Graft-versus-host-disease
DrugAxatilimab
Incyte Corporation
Phase 3
9
Aachen, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Freiburg im Breisgau, Göttingen
2025-06-04
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2025-06-04
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
München, Chemnitz, Berlin, Bochum, Dresden, Erlangen, Kiel
2025-06-01
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Tübingen, Munich, Hamburg, Düsseldorf, Dresden, Lübeck
2025-05-28
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Berlin, Dresden, Frankfurt am Main, Hanover, Mainz, Tübingen
2025-05-28
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
3,103
Amberg, Bad Homburg, Berlin, Dresden, Essen, Falkensee, Frankfurt, Freiburg im Breisgau
2025-05-28
Recruiting
Intelligent Lung Support in the Intensive Care Unit
NCT06595602Mechanical Ventilation, Intensive Care Medicine
Technische Universität Dresden
Observational
530
Dresden
2025-05-25
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Dresden, Berlin, Mainz, Tübingen
2025-05-22
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
4,200
Bad Friedrichshall, Bamberg, Berlin, Bonn, Bünde, Coburg, Dresden, Erfurt
2025-05-20
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Frankfurt am Main, Mainz, Bad Bentheim, Dresden, Hamburg, Heidelberg, Magdeburg, Münster
2025-05-16
Active, closed
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610Hidradenitis Suppurativa (HS)
Zura Bio Inc
Phase 2
225
Bad Bentheim, Bochum, Darmstadt, Dresden, Hamburg, Heidelberg, München, Münster
2025-05-16
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Heidelberg, Villingen-Schwenningen, Frankfurt am Main, Mainz, Dresden, Leipzig, Berlin
2025-05-08
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Immenhausen, Essen, Dresden, Baden, Berlin
2025-05-06
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Aachen, Berlin, Bonn, Dortmund, Dresden, Essen, Frankfurt, Göttingen
2025-05-06
Recruiting
Video-Tumorboard PLUS
NCT06980740Malignant Melanoma, Telemedicine
University Hospital Muenster
Observational
300
Bonn, Dresden, Münster
2025-05-01
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Dresden, Frankfurt
2025-04-29
Recruiting
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
NCT06696183AML - Acute Myeloid Leukemia
DrugsGilteritinib·Azacitidine·Venetoclax
Technische Universität Dresden
Phase 2
60
Dresden
2025-04-25
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Augsburg, Bad Bentheim, Berlin, Bonn, Bramsche, Darmstadt, Dresden, Friedrichshafen
2025-04-15
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Cologne, Dresden, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen
2025-04-09
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Maastricht University
Not applicable
358
Cologne, Dresden, Hanover
2025-04-01
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsTaxotere·Rilvegostomig·Paraplatin·Taxol
AstraZeneca
Phase 3
600
Berlin, Chemnitz, Dessau, Dresden, Düsseldorf, Essen, Hamburg, Kassel
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg
2025-03-27
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640Sepsis, Coagulopathy
DrugBAY3389934
Bayer
Phase 1
36
München, Cologne, Dresden, Leipzig
2025-03-12
Active, closed
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
3,853
Aachen, Bad Homburg, Bad Krozingen, Bad Mergentheim, Bad Oeynhausen, Berlin, Dresden, Elsterwerda
2025-03-12
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Berlin, Dresden, Essen, Hamburg, Marburg
2025-03-12
Recruiting
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT06668181Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
40
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Sankt Augustin, Sendenhorst, Tübingen
2025-03-11
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Bad Homburg, Bamberg, Berlin, Bochum, Brandenburg an der Havel, Dresden, Essen, Friedrichsthal
2025-03-03
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Bad Bentheim, Bad Doberan, Ratingen, Leipzig, Berlin, Dresden, Hamburg, München
2025-03-03
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
2025-02-27
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Bad Bentheim, Berlin, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Minden
2025-02-21
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Genmab
Phase 3
530
Berlin, Bonn, Dresden, Düsseldorf, Essen, Frankfurt, Giessen, Hamburg
2025-02-07
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Dresden, Hamburg, Leipzig, Mainz, Villingen-Schwenningen
2025-02-06
By invitation
A Multicenter, International, Prospective and Retrospective, Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech Paravalvular Leak Device (PLD) in Patients With Mitral or Aortic Paravalvular Leaks
NCT07037446Paravalvular Leak
Occlutech International AB
Observational
200
Berlin, Dresden, München
2025-02-05
Recruiting
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
NCT06897839Bronchopulmonary Dysplasia
Airway Therapeutics, Inc.
Phase 2/3
366
Dresden, Freiburg im Breisgau, Regensburg
2025-02-03
Recruiting
Cyclosporine In Takotsubo Syndrome
NCT05946772Takotsubo Cardiomyopathy
DrugCyclosporine A
University Hospital Heidelberg
Phase 2
204
Bad Nauheim, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2025-02-01
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Langenau, Darmstadt, Dresden, Halle, Berlin, Bochum, Bonn, Erlangen
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Frankfurt am Main, Bochum, Mainz, Dresden, Leipzig, Berlin
2025-01-29
Recruiting
Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula
NCT05843877Periampullary Cancer, Postoperative Pancreatic Fistula
Technische Universität Dresden
Phase 3
32
Dresden
2025-01-28
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Aachen, Berlin, Braunschweig, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen
2025-01-28
Recruiting
Colorectal Resections in Patients With Retroperitoneal Sarcoma
NCT06943612Sarcoma, Soft Tissue, Retroperitoneal Sarcoma
Heidelberg University
Observational
120
Mannheim, Göttingen, Berlin, Cologne, Dresden, Erlangen, Greifswald, Halle
2025-01-27
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774Chronic Graft-versus-host-disease
DrugsAxatilimab·Prednisolone·Methylprednisolone·Prednisone
Incyte Corporation
Phase 3
240
Aachen, Berlin, Bonn, Dresden, Düsseldorf, Erlangen, Essen, Halle
2025-01-21
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126Melanoma, Cutaneous Malignant
DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine
Immatics US, Inc.
Phase 3
360
Cologne, Berlin, Bonn, Dresden, Erlangen, Essen, Frankfurt am Main, Hamburg
2025-01-14
Rows per page Showing 101–200 of 707
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/dresden?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 707 of those studies with a site in Dresden.

How many clinical trials are recruiting in Dresden?

356 of the 707 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 17 have not yet opened recruitment, 321 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.